| Previous Close | 1.4300 |
| Open | 1.4100 |
| Bid | 1.4200 x 3200 |
| Ask | 1.4400 x 40000 |
| Day's Range | 1.3800 - 1.4400 |
| 52 Week Range | 1.2200 - 2.4000 |
| Volume | 983,567 |
| Avg. Volume | 2,968,959 |
| Market Cap | 455.552M |
| Beta (5Y Monthly) | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2880 |
| Earnings Date | Aug. 04, 2021 - Aug. 09, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Geron Announces Two Presentations at Upcoming European Hematology Association Annual Congress
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that two poster presentations of new clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, will be made at the European Hematology Association (EHA) Annual Congress meeting to be held virtually from June 9 - 17. The abstracts for the posters are available on the EHA website at www.ehaweb.org. Both posters will be published on the EHA Virtual Congress platform on June 11, 2021.
- Motley Fool
Geron (GERN) Q1 2021 Earnings Call Transcript
Good day and thank you for standing by and welcome to the Q1 2021 Geron earnings conference call. Welcome to this conference call to discuss Geron's first-quarter 2021 financial results and recent company events.
- Zacks
Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates
Geron (GERN) delivered earnings and revenue surprises of -12.50% and 82.67%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
